【WCLC2018-番外】Slides of Important studies

目录

  • 1 IMpower133: Addition of Atezolizumab to First-line Carboplatin/Etoposide in Extensive-Stage Small-Cell Lung Cancer

  • 2 ALTA-1L: Phase III Trial of Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC

  • 3 PACIFIC: Improved OS With Durvalumab vs Placebo After CRT in Unresectable Stage III NSCLC

  • 4 NELSON: Reduced 10-Yr Lung Cancer Mortality With Low-Dose CT Screening of High-Risk Current and Former Smokers

  • 5 Phase III IMpower132: Addition of Atezolizumab to First-line Carboplatin/Cisplatin + Pemetrexed in Stage IV Nonsquamous NSCLC

  • 6 Phase II ALTER1202: Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond

  • 7 Entrectinib in ROS1-Positive NSCLC: Pooled Analysis of 3 Early-Phase Studies

  • 8 Phase II Study of Poziotinib, an Investigational TKI, in Heavily Pretreated EGFR or HER2 Exon 20–Mutated NSCLC

1 IMpower133: Addition of Atezolizumab to First-line Carboplatin/Etoposide in Extensive-Stage Small-Cell Lung Cancer

2 ALTA-1L: Phase III Trial of Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC

3 PACIFIC: Improved OS With Durvalumab vs Placebo After CRT in Unresectable Stage III NSCLC

4 NELSON: Reduced 10-Yr Lung Cancer Mortality With Low-Dose CT Screening of High-Risk Current and Former Smokers

5 Phase III IMpower132: Addition of Atezolizumab to First-line Carboplatin/Cisplatin + Pemetrexed in Stage IV Nonsquamous NSCLC

6 Phase II ALTER1202: Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond

7 Entrectinib in ROS1-Positive NSCLC: Pooled Analysis of 3 Early-Phase Studies

8 Phase II Study of Poziotinib, an Investigational TKI, in Heavily Pretreated EGFR or HER2 Exon 20–Mutated NSCLC

接下来可能会写点Incretin mimetic drug方面的内容，也算是蹭礼来的热点。

“Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood glucose-dependent mechanism. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. In addition, they inhibit glucagon release from the alpha cells of the islets of Langerhans. The two main candidate molecules that fulfill criteria for an incretin are the intestinal peptides glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as: glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4); both GLP-1 and GIP are members of the glucagon peptide superfamily.”

赞 (0)

相关推荐